It's a Small World After All
The increasing number of US proposals to cut profits for drug companies--usually via price cuts--are far more worrisome to the drug industry than even the Clinton health care proposals of 1993-94. Extrapolating from IMS Health sales data, profits from the US market probably represent considerably more than half of the profits in the worldwide drug industry, a significant change from even a few years ago.
You may also be interested in...
Drug price fixing throughout Europe has long frustrated the pharmaceutical industry, but Pfizer's CEO has singled out France as the worst perpetrator.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.